Qiming Venture Partners has closed funds worth a total $3.2 billion for health care-related investments, with funds spread across the five areas of biopharmaceuticals, med tech, diagnostics, health care services and IT. Read More
Japan’s Ministry of Health, Labor and Welfare has cleared Japan Tissue Engineering Co. Ltd.’s (J-Tec) autologous cultured cartilage, called Jacc, after a seven-year re-examination period. Read More
Precision Autoimmune Therapeutics Co. Ltd. has raised ¥140 million (US$21 million) in its first financing round to speed up its pipeline development and improve its drug development platform. Emerging Technology Partners LLC, Redhill Capital and CASI Pharmaceuticals Inc. participated in the round. Read More
China’s NMPA gave the green light to Simcere Pharmaceutical Group Ltd. for Cosela (injectable trilaciclib hydrochloride) as a treatment to decrease the risk of chemotherapy-induced myelosuppression. It is intended for adult patients with extensive-stage small-cell lung cancer (ES-SCLC), before they undergo a platinum/etoposide-containing regimen. Read More
Amid the ongoing war Russia is waging in Ukraine, representatives of several Western biopharma and medical device companies met with Russian health officials this week to discuss an uninterrupted drug supply, maintenance of medical equipment in Russia and software updates. Russian Minister of Health Mikhail Murashko told the group his agency’s top priority is an uninterrupted drug supply. He recognized that dialogue between the government and manufacturers is necessary to maintain that supply. Read More
Australia’s Therapeutic Goods Administration (TGA) should better align its definitions and classifications for gene, cell and tissue frameworks with international regulators, stakeholders said. Read More
In this multipart special report, BioWorld explores the concept of extending lifespan, which is surprisingly well-validated by basic research. The team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing these potential “Fountain of Youth” candidate drugs. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: ADC, Astrazeneca, Bio-Thera Solutions, Canbridge, Glenmark, Humanigen, Hutchmed, Moderna, Propanc, Sanotize R&D, Telix, Tetra. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Act, Alpha-5 Integrin, Athenex, Daan, Epicentrx, Eurofarma Laboratórios, Genscript Probio, Glycotope, Halberd, Immunoprecise Antibodies, Intron, Kyowa Kirin, Legochem, Pasithea, SK, Ultragenyx. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Beigene, Biontech, Cstone, Dyne, Fresenius Kabi, G1, Moderna, Neurophth, Novavax, Pfizer, Prescient, Rznomics, SCG Cell Therapy, Sinovac, SK. Read More
